PAD - Prescribing Advisory Database
PLEASE NOTE : This is a development system.

For Surrey PAD, please go to https://surreyccg.res-systems.net/PAD.

You are here : Home > PAD Profile : Mercaptopurine - Inflammatory bowel disease

PAD Profile : Mercaptopurine - Inflammatory bowel disease Important

Keywords :
6MP, IBD, UC, Ulcerative Colitis, thiopurines, Crohn's Disease
Brand Names Include :
Puri-Nethol
Important Information :
Tablets and oral suspension are NOT bioequivalent. Do not confuse with mercaptamine (similar name).

Traffic Light Status

Status 1 of 1.

Status :
Amber
Formulations :
  • Oral suspension
  • Tablets
Trust Alignment :
Primary Care
ASPH
RSFT
SASH
SABP
Links :
BNF NICE SPC
SA
Un
Comments :
No comments returned.
Documents :

Guidelines

The following guidelines are available for this indication.

Other Drugs

Other Indications

Additional Documents

Committee Recommendations

Date
Committee Name
Narrative
02 August 2023
Surrey Heartlands Integrated Care System Area Prescribing Committee (APC)

The Surrey Heartlands Integrated Care System Area Prescribing Committee have agreed a local adaptation of the National Shared Care document, in reference to the routine monitoring of CRP (rather than ESR) in primary care for inflammatory indications

05 October 2022
Surrey Heartlands Integrated Care System Area Prescribing Committee (APC)

The Surrey Heartlands Integrated Care System Area Prescribing Committee (APC) has agreed the National Shared Care Protocol for azathioprine and mercaptopurine for patients in adult services (non- transplant indications)

Associated BNF Codes

08. Malignant Disease and Immunosuppression
08.02.01. Antiproliferative immunosuppressants
This site uses its own and third party cookies to function properly and to improve performance, to maintain the session and to personalise user experience, as well as to obtain anonymous statistics about the use of the website. Visit our Privacy and Cookie Policy for more information on our data collection practices. By clicking 'Accept' you agree to our use of cookies for the purposes listed.
Learn More